Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Guinan

Showing results (21-30 of 134) with videos related to

Pageof 14
Sort By:
Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2002
Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell linesM Rubenstein, Y Mirochnik, L Slobodskoy, et al.
Urology|March 1, 1974
Antibodies to epithelium in benign prostatic hypertrophy and carcinoma of prostate. Exacerbation to hyperplasia and neoplasia and possible clue to cancerR J Ablin, P Guinan, I M Bush
Medical Oncology (Northwood, London, England)|March 1, 1997
Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivationM Rubenstein, P Chou, Y Mirochnik, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2003
Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell linesM Rubenstein, L Slobodskoy, Y Mirochnik, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 26, 1999
Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotidesM Rubenstein, Y Mirochnik, P Chou, et al.
Journal of the National Medical Association|December 1, 1991
Prostate cancer: the stage disadvantage in the black maleP V Targonski, P Guinan, C W Phillips
Journal of Surgical Oncology|April 1, 1997
Report of 337 patients with renal cell carcinoma emphasizing 110 with stage IV disease and review of the literatureP Guinan, D Stuhldreher, W Frank, et al.
Archivos Espanoles De Urologia|November 1, 1978
[Transuteral ureterorenoscopy]S Z Muñóz, I M Bush, P Guinan
The Proceedings of the Institute of Medicine of Chicago|May 1, 1973
Carcinoembryonic antigen (CEA) in the plasma and urine of patients with urologic cancerA Thitipraserth, R Ablin, I Bush, et al.
Clinical Physiology and Biochemistry|January 1, 1990
Effect of early and delayed difluoromethylornithine pretreatment upon cyclophosphamide chemotherapyM Johnson, M Shaw, M Rubenstein, et al.
Pageof 14

Showing results (21-30 of 134) with videos related to

Sort By:
Pageof 14
Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2002
Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell linesM Rubenstein, Y Mirochnik, L Slobodskoy, et al.
Urology|March 1, 1974
Antibodies to epithelium in benign prostatic hypertrophy and carcinoma of prostate. Exacerbation to hyperplasia and neoplasia and possible clue to cancerR J Ablin, P Guinan, I M Bush
Medical Oncology (Northwood, London, England)|March 1, 1997
Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivationM Rubenstein, P Chou, Y Mirochnik, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2003
Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell linesM Rubenstein, L Slobodskoy, Y Mirochnik, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 26, 1999
Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotidesM Rubenstein, Y Mirochnik, P Chou, et al.
Journal of the National Medical Association|December 1, 1991
Prostate cancer: the stage disadvantage in the black maleP V Targonski, P Guinan, C W Phillips
Journal of Surgical Oncology|April 1, 1997
Report of 337 patients with renal cell carcinoma emphasizing 110 with stage IV disease and review of the literatureP Guinan, D Stuhldreher, W Frank, et al.
Archivos Espanoles De Urologia|November 1, 1978
[Transuteral ureterorenoscopy]S Z Muñóz, I M Bush, P Guinan
The Proceedings of the Institute of Medicine of Chicago|May 1, 1973
Carcinoembryonic antigen (CEA) in the plasma and urine of patients with urologic cancerA Thitipraserth, R Ablin, I Bush, et al.
Clinical Physiology and Biochemistry|January 1, 1990
Effect of early and delayed difluoromethylornithine pretreatment upon cyclophosphamide chemotherapyM Johnson, M Shaw, M Rubenstein, et al.
Pageof 14